Artur Jurczyszyn

osteoblast proliferation and differentiation in vitro. Eur.J.Haematol. 2010 Oct;85(4):

[119] Zangari M, Esseltine D, Lee CK, Barlogie B, Elice F, Burns MJ, Kang SH, Yaccoby S, Najarian K, Richardson P, et al. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br.J.Haematol. 2005 Oct;131(1):71-3.

[120] Heider U, Kaiser M, Muller C, Jakob C, Zavrski I, Schulz CO, Fleissner C, Hecht M, Sezer O. Bortezomib increases osteoblast activity in myeloma patients irrespective of

[121] Delforge M, Terpos E, Richardson PG, Shpilberg O, Khuageva NK, Schlag R, Dimo‐ poulos MA, Kropff M, Spicka I, Petrucci MT, et al. Fewer bone disease events, im‐ provement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in mul‐

[123] Anderson G, Gries M, Kurihara N, Honjo T, Anderson J, Donnenberg V, Donnenberg A, Ghobrial I, Mapara MY, Stirling D, et al. Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood 2006 Apr 15;107(8):3098-105.

[124] Breitkreutz I, Raab MS, Vallet S, Hideshima T, Raje N, Mitsiades C, Chauhan D, Oka‐ wa Y, Munshi NC, Richardson PG, et al. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 2008

[125] Terpos E, Mihou D, Szydlo R, Tsimirika K, Karkantaris C, Politou M, Voskaridou E, Rahemtulla A, Dimopoulos MA, Zervas K. The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refracto‐ ry/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio. Leukemia 2005 Nov;19(11):1969-76.

[126] Terpos E, Dimopoulos MA, Sezer O. The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma. Leukemia 2007 Sep;21(9):

response to treatment. Eur.J.Haematol. 2006 Sep;77(3):233-8.

tiple myeloma. Eur.J.Haematol. 2011 May;86(5):372-84.

[122] http://www.ema.europa.eu/ema/. 2012 Aug 31.

Oct;22(10):1925-32.

1875-84.

290-9.

240 Multiple Myeloma - A Quick Reflection on the Fast Progress

Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/53385
